ενημερωθείτε:
https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_home
...
https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_home
...
CONCLUSIONS
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.)
Aναγνώσατε: